Exploring Disease Risk and Treatment Options for CML
Dr. Michael Deininger, chief of hematology at the Huntsman Cancer Institute at the University of Utah, explores ongoing research to fine-tune treatment for CML. Dr. Deininger discusses second-generation TKIs in frontline therapy, considerations for switching or ceasing medication, and the need to refine molecular testing into a sophisticated, reliable prognostic method.
Experts & Guests
Michael Deininger, M.D., Ph.D.
Chief of Hematology and Hematologic Malignancies , University of Utah, Huntsman Cancer InstituteMichael Deininger, MD, PhD, is chief of Hematology and Hematologic Malignancies for Huntsman Cancer Institute (HCI) at the University of Utah. He is a professor in the Department of Medicine at the University of Utah. Deininger's clinical interests center on leukemia, myeloproliferative neoplasms and hematopoietic stem cell transplantation. His research focuses on the biology of leukemia and development of molecularly... more >